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EXECUTIVE SUMMARY
Introduction: Post-Operative Nausea and Vomiting (PONV) is a recurrent and frequent
issue for the patient, the anesthesia team, and Post Anesthesia Care Unit (PACU) team.
Both pharmacologic and non-pharmacologic recommended modalities have been utilized
for both the prevention and treatment of PONV in the surgical-anesthesia setting.
The 5-HT3-receptor antagonist ondansetron is one of the many known pharmacological
modalities commonly utilized by anesthesia providers in preventing PONV.
Methodology: The design used for this research was a quantitative, retrospective case
control study that evaluated existing data enclosed in the Electronic Medical Records
(EMR) from Charleston Area Medical Center (CAMC), which is made up of four
hospitals. The sample population included 89 patients: 64 patients with a BMI ≥ 30kg/m2
who have received ondansetron 4 milligrams (mgs) and 25 patients with a BMI ≥
30kg/m2 who have received ondansetron 8 mgs. In this sample population, all of the
patients were 18 to 64 years of age with an American Society of Anesthesiologist (ASA)
I-IV undergoing mastectomy.
Results: There were no statistical significance found between the ondansetron dosage
and the occurrence of PONV. There were no statistical significance found between the
two groups and BMI (p >.05). The mean BMI for ondansetron 4 mgs group was 37
kg/m2 and ondansetron 8 mgs group was also 37 kg/m2. The mean dose of rescue
antiemetic received in the PACU also did not show to be statistically significant between
the two groups (p >.05).
Discussion: Approximately 19% of the patients in this study experienced PONV despite
the intra-operative administration of ondansetron. There were no statistical significance
that was found between the ondansetron dosing and PONV. This may be the result that
the dosing of ondansetron may truly not make a difference in preventing PONV.
Conclusion: The outcome of this study did not express any statistically significant
difference in the 4 mgs and 8 mgs dosing of ondansetron and the occurrence of PONV or
the amount of rescue anti-emetic received in PACU.
Practical Implications: The result of this study did not demonstrate any additional
benefit from a larger dose of 8 mgs compared to a dose of 4 mgs of ondansetron. Dosing
4 mgs may just be as effective as 8 mgs, which simply brings to light that more is not
simply better in all cases. Further research is needed on this topic.
Key Words: Post-operative nausea and vomiting, ondansetron, mastectomy, body mass
index, rescue anti-emetic.
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INTRODUCTION
Background and Significance of the Problem

Post-Operative Nausea and Vomiting (PONV) is a recurrent and frequent issue
for the patient, the anesthesia team, and Post Anesthesia Care Unit (PACU) team. Both
pharmacologic and non-pharmacologic recommended methods have been utilized for
both the prevention and treatment of PONV in the surgical-anesthesia setting. The most
common and distressing symptoms that follow surgery with the utilization of anesthesia
include both emesis and pain (Gupta, Wakhloo, Lahori, Mahajan, & Gupta, 2007).
Prevention and treatment of PONV in surgical procedures that are highly associated with
this risk is usually at the discretion of the anesthesia provider of what they think is the
best regimen for that patient type.
The adverse effects of PONV range from patient related distress to post-operative
life threatening morbidities (Smith, Smith, & Smith, 2012). Patients are willing to
tolerate pain with a higher degree to that of PONV and often rate PONV as worse than
post-operative pain (Gan, 2002). It is not surprising that the prevention of PONV
improves patient satisfaction by those who are highly at risk for it (Darkow, Gora‐
Harper, Goulson, & Record, 2001). Patients were willing to pay United States (US) $56
for an antiemetic that would completely prevent PONV and those who developed PONV,
were willing to pay US $73 and $100 respectively (Gan, Sloan, de L Dear, El-Moalem, &
Lubarsky, 2001).
Patients with no known risk factors carry a 10% risk of PONV, and this risk
increases drastically to 61% and 79% respectively, when 3 or 4 risk factors exists (female
gender, nonsmoker, history of motion sickness, post-operative opioid use, and a history
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of PONV) (Roberts, Bezinover, & Janicki, 2012). Despite the existence of various tools
to categorize those at risk for developing PONV and implementing multiple PONV

prevention and treatment regimens, clinicians do not appear to methodically address these
issues in an identical approach that utilizes both non-pharmacologic and pharmacologic
modalities to minimize PONV (Smith et al., 2012). The research on PONV is vast and

since it is so common, both the prevention and treatment modalities can range from nonpharmacological to pharmacological, or both.
Literature Review
Nausea and vomiting are amongst the most common post-operative disorders that
can occur with various types of anesthesia. The term nausea and vomiting are
intertwined, but yet these remain two separate entities and should be evaluated
individually. Nausea is defined as a subjective unpleasant sensation in which the patient
is aware of the desire to expel gastric contents, but does not necessarily do. Vomiting is
expressed as the expulsion of gastric contents orally by the physical motion of the
contraction of the abdominal muscles, descent of the diaphragm, and opening of the
gastric cardia (Golembiewski, Chernin, & Chopra, 2005).
Because of the physical and emotional stressors of PONV, these consequences
can be seen as life –menacing to the patient. Preventing PONV improves satisfaction
scores among those patients who are at an increased risk of experiencing them (Darkow
et al., 2001). Patients report the avoidance of pain is far less a concern than that of
PONV and although rarely fatal, it can be uncomfortable and be associated with
dissatisfaction with their peri-operative care (Rahmann & Beattie, 2004). Some of these
physical consequences of PONV include sweating, pallor, tachycardia, stomachache,
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increased risk of esophageal rupture, wound dehiscence, and electrolyte imbalance
(Gupta et al., 2007). Multiple physical characteristics related with PONV may be mild,
but the impact on patients and their recovery can be much more severe. Some of these
complications include the inability to mobilize after surgery, restricted oral intake,
delayed recovery, and delayed discharge after surgery (Gan et al., 2007).
There are many risk factors and contributing factors that increase or add to the
effects of PONV. Pre-operative dehydration may occur due to the fact that pre-operative
orders usually include directions to remain nothing-by-mouth (NPO), and can affect postoperative consequences. Because of this NPO status, gut hypoperfusion may occur and is
identified as one of the contributing factors to PONV. To assist with mesenteric
perfusion, likely to prevent PONV, preloading with large volumes of fluids is usually
administered by anesthesia prior to induction (Chaudhary, Sethi, Motiani, & Adatia,
2008). Post-operative patients can have outcomes such as thirst, dizziness, and
drowsiness, and nausea may be predisposed by the little to none patient’s fluid status
intake before and after surgery. The use of opioids in any phase of the surgery can
produce nausea and vomiting by direct stimulation of the chemoreceptor trigger zone
(CTZ), induced delayed gastric emptying, and decreased gastric motility (Bailey, Egan,
& Stanley, 2000).
There are PONV scales available to determine risk factors and or the severity of
PONV in the post-operative phase, which include the Apfel score and the Visual
Analogue Scale (VAS). The Apfel score considers four risk factors: the female gender,
previous history of PONV or motion sickness, non-smoking status, and post-operative
use of opioids (Pierre, Benais, & Pouymayou, 2002). Severity of nausea and vomiting is
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assessed by the (VAS): Score 0- no nausea or vomiting, Score 1- nausea, Score 2retching or mild vomiting, Score 3- two or more vomiting(s) in a 30 minute duration
(Gupta, & Jain, 2014).
PONV is a common complication that patients experience following breast
surgery (Watwill et al., 2003). The stated occurrence of PONV in patients undergoing
breast surgery with axillary dissection is about 60-80% (Fujii, 2006). The pharmacologic
drugs, which include 5-HT3 receptor antagonists, are widely used drugs given routinely
by anesthesia providers as a first line modality in the prevention of PONV. Because
breast surgery is commonly associated with PONV, the modalities to help prevent and or
treat PONV are comprised of multimodal therapies that utilize both non-pharmacological
and pharmacological programs.
Many modalities to prevent and treat PONV have been utilized by anesthesia in
recent decades. Some non-pharmacologic and alternative techniques for the prevention
and treatment of PONV include, but are not limited to, acupuncture, electro-acupuncture,
acupoint stimulation, acupressure, transcutaneous nerve stimulation, ginger, hypnosis,
and aromatherapy (Golembiewski, et al., 2005). The most commonly used method to
treat severe PONV is the administration of an intravenous (IV) anti-emetic agent that
obstruct emetogenic neurotransmitters (NT) at the level of the CTZ located within the
brain. Some of these NT include serotonin (5-HT3), dopamine, histamine, and
acetylcholine. The introduction of 5-HT3 receptor antagonists was a major breakthrough
in the 1990’s and represented a major development in pharmacotherapy in regards to
treatment regimens that induced nausea and vomiting (Radford, Fuller, Bushey, Daniel,
& Pellegrini, 2011). Ondansetron was the first drug to be introduced and is the most
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commonly used drug in the class of 5-HT3 receptor antagonists (Ku, & Ong, 2003).
According to Golembiewski et al. (2005), the recommended dose for ondansetron in
an adult is 4 milligrams (mgs), but Ku and Ong state that the optimal prophylactic

intravenous dose of ondansetron is 8 mgs for long-term efficacy (Ku & Ong, 2003).

The clinical side effect of the drug ondansetron includes the commonly reported
headache and the ability to prolong the QT interval on the electrocardiogram

(Butterworth, Mackey, Wasnick, Morgan, & Mikhail, 2013). For these reasons, the

clinician administering the drug must be vigilant in understanding the
pharmacodynamics and clinical side effects of ondansetron.

In this study, the researcher planned to investigate a common prophylactic

prevention and treatment of PONV utilized at Charleston Area Medical Center (CAMC)
to determine if there was a decrease in the occurrence of PONV.
Statement of the Problem and Research Purpose
PONV is a common issue at CAMC, and because there are a multitude of
prevention and treatment regimens among varying anesthesia providers, an investigation
of a commonly utilized prophylactic treatment was complete. A mutual practice at
CAMC is the administration of ondansetron 8 mgs in obese patients instead of the
standard dose of ondansetron 4 mgs.
The purpose of this retrospective investigation is to determine if patients with a
BMI ≥ 30kg/m2 undergoing mastectomy procedure, who have received ondansetron 4
mgs intra-operatively, experienced more PONV than those who have received
ondansetron 8 mgs.
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Another purpose of this investigation is to determine if obese patients with a BMI
≥ 30kg/m2 who experienced PONV after receiving ondansetron 4 mgs intra-operatively,
required more rescue anti-emetic medication than those who received ondansetron 8 mgs.
If this is so, facilities can possibly implement the use of 4 mgs of ondansetron
instead of 8 mgs on patients with a BMI ≥ 30kg/m2 undergoing mastectomy, and can
reduce the costs associated with the assumption that BMI’s ≥ 30kg/m2 require more
pharmacological interventions. By utilizing the minimal amount of ondansetron, needed
to prevent PONV, can this also reduce the associated side effects seen with ondansetron?
METHODOLOGY
Research Hypothesis
This retrospective study was analyzed using the hypotheses: 1) In a group of ASA
I-IV adult patients with a BMI ≥ 30kg/m2 undergoing a mastectomy procedure who
received 4 mgs of ondansetron, there will be fewer incidences of PONV than those who
received 8 mgs. 2) In a group of ASA I-IV adult patients with a BMI ≥ 30kg/m2
undergoing a mastectomy procedure that received 4 mgs of ondansetron will require less
amounts of rescue anti-emetic given than those who received 8 mgs.

Research Design and Setting
The design used for this research was a quantitative, retrospective case control
study evaluating existing data enclosed in the Electronic Medical Records (EMR) from
Charleston Area Medical Center (CAMC), which is made up of four hospitals.
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Sample Population with Description
The sample population used for this retrospective study included female patients
who underwent a unilateral simple mastectomy and bilateral simple mastectomy at
CAMC Health System between January 1, 2005 and June 1, 2015. Males in this study
were excluded due to only 10 males or 2 percent out of 363 charts were analyzed and
only 3 males or 30 percent of all males made the inclusion criteria. The sample included
64 patients ages 18-64, measured in years, with a BMI greater than or equal to 30 kg/m2
who received ondansetron 4 mgs and 25 patients with a BMI greater than or equal to 30
kg/m2 who have received ondansetron 8 mgs. The patients were identified using the
following ICD10 procedure code: 85.41 unilateral simple mastectomy and 85.42 bilateral
simple mastectomy.
Inclusion Criteria:
1. Adult patients 18 to 64 years of age.
2. Patients with American Society of Anesthesiologists (ASA) physical status I-IV.
3. Patients who underwent general anesthesia for mastectomy with a BMI greater
than or equal to 30 kg/m2 and received either ondansetron 4 mgs or ondansetron 8
mgs.

Exclusion Criteria:
1. Patients that have a history of PONV.
2. Patients that have a history of a gastrointestinal (GI) disorders such as Crohn’s
disease, Ulcerative Colitis (UC) or Irritable Bowel Syndrome (IBS).
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3. Patients that received any other anti-emetic or medications that are known to have
anti-emetic properties (i.e. Benadryl).
4. Patients 17 years of age and younger or 65 years of age and older.
5. Patients with an ASA physical status V-VI.
6. Patients who underwent general anesthesia for mastectomy with a BMI less than
30 kg/m2 and received either ondansetron 4 mgs or ondansetron 8 mgs.
Procedure and Protocol
A retrospective chart review was completed on patient records that have
undergone mastectomy at CAMC Health System from January 1, 2005 to June 1, 2015.
To test the hypothesis, the following variables were collected: ondansetron dosage (4 mg
versus 8 mg), BMI, occurrence of PONV, amount of rescue anti-emetic for PONV in the
PACU, age, gender, and ASA status. BMI is defined as a numeric calculation based on
the patient’s weight and height for evaluation of patient’s body fatness for most people
(CDC, 2015). Nausea is defined as a subjective unpleasant sensation in which the patient
is aware of the desire to expel gastric contents, but does not necessarily do. Vomiting is
expressed as the expulsion of gastric contents orally by the physical motion of the
contraction of the abdominal muscles, descent of the diaphragm, and opening of the
gastric cardia. Obesity is identified as a BMI greater than or equal to 30kg/m2 and a BMI
of greater than or equal to 30kg/m2 , is to be considered obese for this study (CDC, 2015).
The utilization of rescue anti-emetic(s) is to be associated as a pharmacological agent(s)
used for the treatment of PONV. Age is to be labeled as 18 to 64 years. Gender is to be
classified as male or female. Physical health status of each patient will be determined
using ASA numerical scale from I-VI (ASA, 2015). For the purpose of this study,
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patients with a physical status of I-IV are to be incorporated. The ASA classifications
are:
1. A normal healthy patient.
2. A patient with mild systemic disease.
3. A patient with severe systemic disease.
4. A patient with severe systemic diseases that is a constant threat to life.
Data Collection and Instruments
Data collection was conducted by using existing data from each patient’s
individual EMR. Each patient was given a number in the order in which the data was
collected and the number in no way linked the data collected to the patient it belonged to.
Individual data used was collected from the pre-operative anesthesia assessment flow
sheet, anesthesia record, and the PACU patient documentation sheet.
Detailed data used was collected from the pre-anesthesia evaluation, anesthesia
record and the PACU patient documentation during the patient’s time in the recovery
phase at CAMC Health System. The anesthesia record flow sheet used on each patient
undergoing anesthesia at CAMC contained enclosed information including: surgical
procedure, significant times in the operating room, medications administered, vital trends,
and other patients’ surgical data. The PACU at CAMC General, Memorial, Woman and
Children’s, and Teays Valley hospitals cares for the patient’s needs immediately after
surgery until patients have stabilized and are able to be transferred to a nursing floor or
discharged home.
The PACU flow sheet was used to record patient data during the time that the
patient was in the recovery room after surgery. The PACU flow sheet enclosed material

9

that was collected for the study including: the occurrence of nausea and vomiting and the
dosages of the rescue anti-emetic administered.
Data collection worksheets were established to aid in collection and organization
of patient data. Data Collection Worksheet 1 was used to assign each patient a study
participant number that was linked to each patient’s identification number in order to
protect patient identity (Appendix A). Data Collection Worksheet 2 served to organize
data for gender, age, height, weight, ASA, ondansetron dosage intra-operatively,
occurrence of PONV, amount and usage of rescue antiemetic (Appendix B). All data
collected were recorded using these two data collection tools designed by the researcher
for this study.
Statistical Design and Analysis
The purpose of this study was to determine if patients with a BMI ≥ 30kg/m2
undergoing mastectomy procedure, who have received ondansetron 4 mgs intraoperatively, experienced more PONV than those who have received ondansetron 8 mgs.
Another purpose of this investigation was to determine if obese patients with a BMI ≥
30kg/m2 who experienced PONV after receiving ondansetron 4 mgs intra-operatively,
required more rescue anti-emetic medication than those who received ondansetron 8 mgs.
Independent variables in this study included: age, BMI, ASA physical status, and
ondansetron dosage. Dependent variables analyzed were: PONV and dosage of rescue
antiemetic required for relief of PONV.
The Pearson Chi-square was used to determine if there was a statistical significant
difference between the ondansetron dosing groups with regards to physical status. The
Fisher’s exact test was used to assess the statistical significance
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of the occurrence of PONV and ondansetron dosing of 4 mgs and 8 mgs.
A student t-test was used to determine if there was a statistical significant
association between the two groups in regards to age and BMI. A student t-test was used
to determine the difference between the mean doses of ondansetron and promethazine
received in the PACU between both groups. A logistical regression was used to
determine if there was a relationship between ondansetron dosage intra-operative and the
occurrence of PONV, age, BMI, and ASA. The logistical regression was again used to
determine if there was an association between the rescue anti-emetic dose of
promethazine and ondansetron and the intra-operative dose of ondansetron, age BMI, and
ASA. The level of statistical significance was set at p < .05.
Ethical Considerations
This study was approved by CAMC and West Virginia University/Charleston
Division Institutional Review Board on September 1, 2015 (Appendix C).

RESULTS
The mean age of all patients was 53 years with 100% of the population being
female. From a total of 89 patients that were included in the study, 71% of patients
received ondansetron 4 mgs dosing intra-operatively (ondansetron 4 mgs group) and 28%
of patients received ondansetron 8 mgs dosing intra-operatively (ondansetron 8 mgs
group), (Table 1). The independent samples t-test did not show a statistically significant
difference between the mean age between ondansetron 4 mgs and ondansetron 8 mgs
groups (p >.05),
The mean BMI for all patients was 37 kg/m². The mean BMI of patients
receiving ondansetron 4 mgs was 37 kg/m² while the mean BMI of patients receiving
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ondansetron 8 mgs was also 37 kg/m². The independent samples T-test did not show a
statistically significant difference between the mean BMI between ondansetron 4 mgs
and ondansetron 8 mgs groups (p >.05), (Table1).
Most of the total patients in the study were ASA status II and III classifications
(Table 1). Thirty- four percent of the total patients in the study were ASA I and II
classifications, with 32% receiving ondansetron 4 mgs and 40 % receiving ondansetron 8
mgs. Fifty-eight of the total patients in the study were ASA III and IV classification,
with 67% receiving ondansetron 4 mgs and 60% receiving ondansetron 8 mgs (Table 1).
The Pearson Chi-square test did not show a statistically significant difference between the
ASA status between ondansetron 4 mgs and ondansetron 8 mgs groups (p >.05),
(Table1).
Table 1: Clinical Characteristics of Female Patients Undergoing Mastectomy Receiving
Intraoperative Ondansetron 4 milligrams and Ondansetron 8 milligrams

Variable

Total
(N= 89)

Ondansetron
4mgs
(N=64)

Ondansetron
8mgs
(N=25)

PValue

53

53

52

NS T

89
(100)

64
(100%)

25
(100%)

NSTT

37

37

37

NST

31
(34%)

21
(32%)

10
(40%)

NSTT

Age (years)
Mean Age
Gender
Female
BMI (kg/m²)
Mean BMI
ASA Physical Status
Classification
I & II

58
43
15
NSTT
(65%)
(67%)
(60%)
*Indicates Statistical Significance at p < .05, NS = Not Significant, kg/m²=kilograms per
meters squared. Fisher’s Exact not completed for cells less than 5. T Indicates T-test
TT Indicates Pearson Chi-square test
III & IV
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Seventeen total patients experienced PONV in the study (Table 2). Twenty- three
percent of patients who received ondansetron 4 mgs intra-operatively experienced PONV
compared to 8% of patients who received 8 mgs ondansetron intra-operatively (Table 2).
The difference in the occurrence of PONV between the patients who received
ondansetron 4 mgs and ondansetron 8 mgs intra-operatively was not found to be
statistically significant (p >.05), (Table 2).
Table 2: Comparison Between Patients Receiving Ondansetron 4 milligrams and
Ondansetron 8 milligrams and Occurrence of Post-operative Nausea and Vomiting
Utilizing the Fisher’s Exact Test
Variable

Total
(N = 89)

Ondansetron 4 mgs
(N = 64)

Ondansetron 8 mgs
P(N = 25)
Value

Occurrence of
PONV
17
15
2
(19%)
(23%)
(8%)
72
49
23
No
(80%)
(76%)
(92%)
*Indicates Statistical Significance at p < .05, NS = Not Significant, PONV = Post
operative Nausea and Vomiting, mgs = milligrams
Yes

NS

Seventeen total patients in the study experienced PONV and most received a
rescue anti-emetic (Table 3 a). Fifteen of these patients were in the ondansetron 4 mgs
group and received an average dose of 4.16 mgs of promethazine (Table 3 a). Two
whom experienced PONV were in the ondansetron 8 mgs group and received an average
dose of about 1.68 mgs of promethazine (Table 3 a). In a t-test comparison, there were
no statistically significant differences in the dosing of promethazine rescue anti-emetic
between these groups (p >.05), (Table 3 a).
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Table 3 a: A T-test Measuring Association Between Dosing of Promethazine for Rescue
Anti-emetic in Post-Anesthesia Care Unit Between Patients Receiving Ondansetron 4
milligrams and Ondansetron 8 milligrams
Variable
Intra-operative
Ondansetron
dosing
4 mgs
8 mgs

Total
(N = 17)

Promethazine
dose (mgs),
Mean

Std.
Deviation

15
2

4.16
1.68

4.5
2.3

PValue

NS

*Indicates Statistical Significance at p < .05, NS = Not Significant, mgs = milligrams

Seventeen total patients in the study experienced PONV and received rescue
antiemetic (Table 3 b). Fifteen of these patients were in the ondansetron 4 mgs group and
received an average dose of 1.86 mgs of ondansetron in the PACU (Table 3 b). Two
whom experienced PONV were in the ondansetron 8 mgs group and received an average
dose of 0 mgs of ondansetron in the PACU (Table 3 b).
Table 3 b: A T-test Measuring Association Between Dosing of Ondansetron for Rescue
Anti-emetic in Post-Anesthesia Care Unit Between Patients Receiving Ondansetron 4
milligrams and Ondansetron 8 milligrams

Variable
Intra-operative
Ondansetron
dosing
4 mg
8 mg

Total
(N = 17)

Ondansetron
dose (mgs),
Mean

15
2

1.86
0

The Binary Logistic Regression analysis showed that there were no statistical
significant associations between PONV and those who received rescue anti-emetic, and
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the rest of the variables: age, BMI, ASA, ondansetron intra-operative dose (p >.05),
(Table 4).
Table 4: Using Binary Logistic Regression for Post –Operative Nausea and Vomiting in
Females Undergoing Mastectomy Receiving Rescue Anti-emetic Analysis

Step 1

B

S.E

Wald

df

Sig.

Exp
(B)

-.030

.036

.722

1

.395

.970

-.034

.047

.505

1

.477

.967

95%
Confidence
Sig.
Interval of
(2the
tailed) Difference
(Upper)

P-Value

Age (years)
.415

5.2659

NS

3.0487

NS

BMI (kg/m²)
.937

ASA
.368 .549 .450
1 .502 1.445
NS
Ondansetron
.314 .201 2.429 1 .119 .731
dose in mgs
NS
Constant
2.002 2.963 .457
1 .499 7.404
NS
Rescue drug
Promethazine
.139
1.9674
NS
in mgs
Rescue drug
Ondansetron
.087
.93945
NS
in mgs
Indicates Statistical Significance at p < .05, kg/m²=kilograms per meters squared, mgs =
milligrams, (-) = no value indicated, NS= Not Significant
The Binary Logistic Regression analysis showed that there were no statistical
significant association between PONV and the rest of the variables: age, BMI, or
ondansetron intra-operative dose (p >.05), (Table 5).
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Table 5: Using Binary Logistic Regression for Post –Operative Nausea and Vomiting in
Females Undergoing Mastectomy Analysis

B

95%
Confidence
Interval of
the
Difference
(Upper)

P-Value

(Constant)
2.002
NS
Age (years)
-.030
5.2659
NS
BMI
3.0487
-.034
NS
(kg/m²)
Ondansetron
4 mgs
NS
-.314
Ondansetron
8 mgs
* Indicates Statistical Significance at p < .05, NS = Not Significant, kg/m²=kilograms per
meters squared, mgs = milligrams, (-) = no value indicated

DISCUSSION
Discussion of Study Results
Despite all of the female patients in this study receiving an intra-operative dosing
of ondansetron, about 19% still experienced PONV and is consistent with current
literature that being a female is a risk factor that increases the risk for PONV (Eberhart,
et al., 2004). The independent samples T-test did not show a statistically significant
difference association between the mean age and BMI between ondansetron 4 mgs and
ondansetron 8 mgs groups. The Pearson Chi-square test did not show a statistically
significant difference in association between the ASA physical status and ondansetron 4
mgs and ondansetron 8 mgs groups. Literature studies correlate that the BMI and ASA
physical status is not a significant predictor of PONV, but according to the Apfel risk
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model for the probability of PONV, female gender, non-smoking, history of PONV, and
the use of post-operative opoids are (Choi, Ko, Ahn, & Kim, 2005).
The Fisher’s exact test was used to determine if there was an association between
ondansetron dosing and the occurrence of PONV, but there was no statistical
significance. Per existing literature, ondansetron is recommended to be given at the end
of the case and not at the start of it, and some of the patients were noted to have an intraoperative dose at the start of the case, which may contribute to why some patients still
developed PONV despite receiving a dose of intra-operative ondansetron (Quaynor &
Raeder, 2002). Another plausibility concluding that there was no statistical significance
association between dosing and PONV may have been that 8 mgs of ondansetron offers
no greater efficacy than 4 mgs intravenously as evidenced by standing literature
(Golembiewski, Chernin, & Chopra, 2005). In this instance, more of ondansetron may
not simply mean there will be a lesser chance of PONV.
There was no statistically significance found between the intra-operative
ondansetron dosing groups and the mean doses of rescue anti-emetics (promethazine/
ondansetron) received in the PACU utilizing the T-test formula. This could perhaps be
expounded by other treatment modalities performed by the PACU team such as
intravenous fluids, application of supplemental oxygen, or treatment of a low blood
pressure, which can contribute to nausea and vomiting. Existing literature states that
non-pharmacological modalities such as hydration and maintaining blood pressure have
been shown to be effective in treating and preventing PONV (Golembiewski & O’Brien,
2002).
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The result of the binary logistical regression analysis showed that there was not a
statistical significant association between PONV and the rest of the variables: age, BMI,
or ondansetron dosing. As evidenced by literature studies, there may be no association
between PONV and the variables age and BMI, suggesting that ondansetron dosing may
not make a difference in the occurrence of PONV (Jaffe, Campbell, Bellman, & Baildam,
2000).
The outcome of the binary logistical regression analysis showed that there was not
a statistical significant association between the administration of rescue anti-emetic
dosing and the rest of the variables: age, ASA, BMI, or intra-operative ondansetron
administration. A multi-modal approach to decrease PONV involves the utilization of
both pharmacological and non-pharmacological prophylaxis to reduce the baseline risk
such as hydration, oxygen, and blood pressure support, which is a continuation modality
in the PACU setting where the rescue anti-emetic dose would be administered (Gan et al.,
2007). This may suggest that the dosing of the rescue anti-emetic when PONV is present
had no association with the intra-operative dosing of ondansetron, age, ASA, or BMI.
Study Limitations
A limitation to this retrospective study would consist that this may not provide
definite information about the cause-and-effect relationship. A more causal type of
design would consist of a longitudinal study, which is observational like the crosssectional design, except these studies extend beyond a single moment and can establish
sequence of events (IWH, 2015). Errors and omissions can result in poor documentation
and or misinterpretation of data, especially in a retrospective study.
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A total of 363 charts were analyzed due to only 363 patients were coded for the
two ICD 10 codes of 85.41 and 85.42. between January 1, 2005 to June 1, 2015, and only
89 charts or 24% of them met the inclusion criteria requirements. Out of the 363 charts,
only 10 were male or 2%, and because of a small percentage that made the inclusion
criteria, there were not any male patients that were included in the study. Mastectomies
in males, for the treatment of breast cancer, is rare due to the disease in males is
uncommon and accounts for only one percent of all breast cancers diagnosed in the world
wide annually (Korde et al., 2010).
Another limitation in this study includes a skewed amount of ondansetron given
in which 71% of the patients received 4 mgs and only 28% received 8 mgs in the 89
patients that were part of the inclusion criteria. This may have been due to provider
preference due to caution taken with higher doses as to minimize the side-effect
associated with ondansetron, which most commonly is that of a QT interval prolongation
on an electrocardiogram reading (Kator, & Kim, 2015).
When assessing all 89 charts, there was not a single patient that received more
than 8 mgs of ondansetron, including the pre-operative, intraoperative, and postoperative
periods, and this may be associated with that 8 mgs may be the maximum one feels
confortable giving because of the unwanted side-effects or they may assume it is not
effective and or switch to another anti-emetic. According to the US Food and Drug
Administration (FDA), an update in 2012 states that GlaxoSmithKline (GSK) has
announced changes to the label of the drug Zofran or ondansetron, stating its use in adults
and children with chemotherapy-induced nausea and vomiting at the lower intravenous
dose recommended in the drug label, a dose of 0.15 mg/kg administered every 4 hours for
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three doses. High doses of ondansetron, such as 32 mgs in a single intravenous
administration may affect the electrical activity of the heart and can pre-dispose the
patient to abnormal or potentially fatal heart rhythms (FDA, 2011). Because of the risk
of pre-disposing patients to unwarranted side-effects associated with higher dosages of
ondansetron within the perioperative period, of those patients who received 8 mgs
intraoperative, they were not given an additional dose of ondansetron as a rescue antiemetic in PACU and instead promethazine was given, causing the data to be skewed with
zero patients receiving ondansetron.
An additional limitation could have been poor documentation on the PACU flow
sheet was a common trend noticed, possibly related to charting in 15 minutes increments
such as inconsistencies with anti-emetic given, but there was no indication of PONV.
Poor quality or missing information may significantly affect the results of a retrospective
statistical investigation (Braaf, Manias, Riley, 2011).
Additional treatment modalities in the anesthesia-surgical setting and or PACU
may have helped with the prevention and or treatment of PONV including but not limited
to, anxiolytic administration, low-dose of neuromuscular blocking drug such as
neostigmine, which in high-doses can cause PONV, and adequate intravenous fluid
resuscitation of crystalloids and colloids (Chandrakantan, & Glass, 2011).

These

influences were not examined as part of this study, which thereby could amend the
results.

CONCLUSION
There was not any statistically significant difference in the 4 mgs and 8 mgs dosing of
ondansetron and the occurrence of PONV or the amount of rescue anti-emetic received in
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PACU. In this study, 4 mgs ondansetron intra-operatively dosing was associated with the
same prevention of PONV and utilization of rescue anti-emetics compared to the 8 mgs
dosing of ondansetron.

IMPLICATIONS AND RECOMMENDATIONS
Prevention of PONV is crucial for both the patient’s safety and satisfaction enduring any
surgical procedure. Multimodal prevention and treatment modalities are at the discretion
of the anesthesia provider, and the norm of the environment may also affect their choices.
Dosing 4 mgs may just be as effective as 8 mgs, which simply brings to light that more is
not simply better in all cases. The results of this study can allow for a more cost-effective
treatment plan when utilizing the drug ondansetron resulting in cost savings for both the
facility and patient, and decrease associated side effects seen with higher dosing of
ondansetron. The study of this research may contribute to the anesthesia providers in
planning appropriately for each individual patient in the prevention of PONV. Further
research is needed on this topic.
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APPENDIX A: DATA COLLECTION WORKSHEET #1

PIN#

Study Participant #
1
2
3
4
…
89
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APPENDIX B: DATA COLLECTION WORKSHEET #2
Study
Gender Age BMI
ASA
Ondersetron Occurrence Promethazine Ondansetron
Participant
Physical
Dose
of
in
in
#
Status
Intra-op
PACU
PACU
PONV
I-IV
Y=yes
(mgs)
(mgs)
N= no
1
2
3
4
…
89
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